Global Ilumya Sales (FY24)
$580M
+21.7% YoY
Ilumya global sales grew 21.7% to $580M in FY24, driven by US and international expansion.
SUNPHARMA
Healthcare
15 May 2024
Sunpharma Ltd — Q4 FY24
Sun Pharma reported Q4 FY24 consolidated revenue of INR 11,813 crore, up 10.1% YoY, driven by strong specialty sales (Ilumya up 21.7% to $580M globally) and India formulation growth of 10.2%.
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Sun Pharma reported Q4 FY24 consolidated revenue of INR 11,813 crore, up 10.1% YoY, driven by strong specialty sales (Ilumya up 21.7% to $580M globally) and India formulation growth of 10.2%. EBITDA margin contracted 30bps to 25.3% due to higher R&D and selling expenses. PAT grew 33.8% to INR 2,655 crore, aided by lower tax. Management guided for high single-digit revenue growth in FY25, with R&D spend rising to 8-10% of sales as the company invests in specialty pipeline (deuruxolitinib launch, phase III for MM2). Key risks include FDA compliance issues at Mohali/Dadra, potential pricing pressure from Stelara biosimilars, and elevated investment costs impacting near-term margins.
सन फार्मा ने चौथी तिमाही में 11,813 करोड़ रुपये की कमाई की, जो पिछले साल से 10.1% ज्यादा है। इसकी वजह है खास दवाओं (जैसे इलुम्या की बिक्री 21.7% बढ़कर 580 मिलियन डॉलर हुई) और भारत में दवा बिक्री में 10.2% का उछाल। मुनाफा 33.8% बढ़कर 2,655 करोड़ रुपये हो गया, क्योंकि टैक्स कम लगा। कंपनी ने अगले साल 8-10% तक कमाई बढ़ने का अनुमान लगाया है, लेकिन नई दवाओं पर ज्यादा खर्च करेगी। जोखिमों में फैक्ट्रियों पर एफडीए की पाबंदी, स्टेलारा जैसी दवाओं से मुकाबला और बढ़ते निवेश से मुनाफे पर दबाव शामिल है।
Key Numbers
India Market Share
8.5%
+20bps YoY
Sun Pharma's India market share improved to 8.5% from 8.3% a year ago, maintaining #1 rank.
US Specialty Sales (Q4)
$271M
+11.1% YoY
Global specialty sales reached $271M in Q4, up 11.1% YoY, led by Ilumya and Cequa.
R&D Spend as % of Sales (Q4)
7.6%
+100bps YoY
R&D spend was 7.6% of sales in Q4, with specialty R&D accounting for 42% of total.
What Changed vs Last Quarter
NEW
High single-digit consolidated revenue growth for FY25
Management expects consolidated top-line growth in high single digits for FY2025, driven by all business segments.
NEW
R&D spend to be 8-10% of sales in FY25
R&D investments will increase to 8-10% of sales for the next year, primarily for specialty pipeline.
NEW
Deuruxolitinib launch post-PDUFA date (July 2024)
Deuruxolitinib is on track for launch after the July 2024 PDUFA date, with pre-launch costs already being incurred.
DROPPED
R&D spend to touch lower end of 7% guidance for FY24
Management indicated that R&D spend for the full year is expected to reach the lower end of the 7% of sales guidance.
DROPPED
Phase II/III trials for MM-II and GL0034 to start in H2 2024
Phase III for MM-II and Phase II for GL0034, initially expected early 2024, are now slated to begin in the second half of 2024.
DROPPED
Nidlegy filing with European authorities in H1 2024
Partner product Nidlegy is expected to be filed with European authorities during the first half of 2024.
NEW RISK
FDA compliance issues at Mohali and Dadra plants
OAI status and 483 observations at Mohali and Dadra facilities could impact US generic launches and revenue.
NEW RISK
Elevated R&D and launch costs pressuring margins
Higher R&D spend (8-10% of sales) and deuruxolitinib launch costs may compress EBITDA margins in FY25.
NEW RISK
Pricing pressure from Stelara biosimilars
Stelara biosimilar entry next year could impact Ilumya pricing and market share in the US psoriasis market.
NEW RISK
Currency depreciation in emerging markets
Nigeria forex loss and broader emerging market currency volatility could impact reported revenue and profitability.
RISK GONE
Mohali plant supply constraints persist
Supplies from Mohali plant are not normal; issues with product prioritization and quality clearances are causing delays.
RISK GONE
CEQUA facing increased competition in dry eye space
CEQUA's market share has declined due to generic Restasis and new entrants with different mechanisms of action.
RISK GONE
Red Sea supply chain disruption risk
Management is monitoring the Red Sea situation; potential for shipment delays if situation does not normalize.
RISK GONE
Taro merger may not receive minority approval
The $43/share offer requires approval from Taro's minority shareholders; failure could derail the merger.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q2 FY24
Management aims to grow India formulation business faster than the Indian pharmaceutical market on an annualized basis.
Mentioned in Q1 FY24, Q3 FY24
Supplies from Mohali plant are not normal; issues with product prioritization and quality clearances are causing delays.
Management Guidance
High single-digit consolidated revenue growth for FY25
Management expects consolidated top-line growth in high single digits for FY2025, driven by all business segments.
Management guidance revenueR&D spend to be 8-10% of sales in FY25
R&D investments will increase to 8-10% of sales for the next year, primarily for specialty pipeline.
Management guidance growthDeuruxolitinib launch post-PDUFA date (July 2024)
Deuruxolitinib is on track for launch after the July 2024 PDUFA date, with pre-launch costs already being incurred.
Management guidance expansionKey Risks
FDA compliance issues at Mohali and Dadra plants
OAI status and 483 observations at Mohali and Dadra facilities could impact US generic launches and revenue.
high · analyst_questionElevated R&D and launch costs pressuring margins
Higher R&D spend (8-10% of sales) and deuruxolitinib launch costs may compress EBITDA margins in FY25.
medium · management_commentaryPricing pressure from Stelara biosimilars
Stelara biosimilar entry next year could impact Ilumya pricing and market share in the US psoriasis market.
medium · analyst_questionCurrency depreciation in emerging markets
Nigeria forex loss and broader emerging market currency volatility could impact reported revenue and profitability.
low · data_observationNotable Quotes
Our focus would be that how do we increase the spend without negatively impacting our overall profitability? How much we are able to execute is something that we will see.
We feel that we've done enough corrections so that we should see a positive outcome in subsequent audits.
We broadly see an acceptance that we have a strong product in our hands.
Frequently Asked Questions
What was Sunpharma's revenue in Q4 FY24?
Sunpharma reported revenue of ₹11,813 Cr in Q4 FY24, representing a +10.1% change compared to the same quarter last year.
What guidance did Sunpharma management give for FY25?
High single-digit consolidated revenue growth for FY25: Management expects consolidated top-line growth in high single digits for FY2025, driven by all business segments. R&D spend to be 8-10% of sales in FY25: R&D investments will increase to 8-10% of sales for the next year, primarily for specialty pipeline. Deuruxolitinib launch post-PDUFA date (July 2024): Deuruxolitinib is on track for launch after the July 2024 PDUFA date, with pre-launch costs already being incurred.
What are the key risks for Sunpharma in FY25?
Key risks include FDA compliance issues at Mohali and Dadra plants — OAI status and 483 observations at Mohali and Dadra facilities could impact US generic launches and revenue.; Elevated R&D and launch costs pressuring margins — Higher R&D spend (8-10% of sales) and deuruxolitinib launch costs may compress EBITDA margins in FY25.; Pricing pressure from Stelara biosimilars — Stelara biosimilar entry next year could impact Ilumya pricing and market share in the US psoriasis market.; Currency depreciation in emerging markets — Nigeria forex loss and broader emerging market currency volatility could impact reported revenue and profitability..
Did Sunpharma meet its previous quarter's guidance?
Of 2 tracked promises, management 0 met, 1 close, 1 missed.
Where can I read the full Sunpharma Q4 FY24 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary with filing verification status shown on the financial stats.